• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

伊维菌素在感染盘尾丝虫的苏丹和墨西哥患者血浆及组织中的摄取与分布。

Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus.

作者信息

Elkassaby M H

机构信息

Department of Pathology, Michigan State University, East Lansing 48824-1316.

出版信息

Trop Med Parasitol. 1991 Jun;42(2):79-81.

PMID:1896777
Abstract

Ten Sudanese patients with Onchocerca volvulus infection were treated with a single oral dose of 150 micrograms/kg of ivermectin. Plasma samples were collected before treatment, 0.5, 1, 3, 4, 6, 12 hours and 1, 2, 3, 7, and 30 days. Four patients were selected for nodulectomies and skin biopsies at 6, 18 and 30 hours and 3 days post treatment. Using these samples O. volvulus worm fragments were dissected free of host nodular tissues for ivermectin extraction. Ivermectin was present in the nodular tissue at 6 hr and persisted for 3 days. It was also detected in an individual worm tissue extract at a concentration similar to the nodule, but in subcutaneous fascial tissue higher concentrations were sometimes found. Ivermectin was detected by radioimmunoassay in the plasma of all patients at 1 hr and peak concentrations were reached in an average of 5.6 hr. The drug persisted at detectable levels for 7 days in 70% of the studied patients. Plasma samples were also collected from 16 treated Mexican onchocerciasis patients before ivermectin treatment and 4 hr treatment and from six individuals who served as controls. The Mexican patients had concentrations of ivermectin in their plasma similar to those in the Sudanese patients.

摘要

10名感染盘尾丝虫的苏丹患者接受了单剂量口服150微克/千克伊维菌素的治疗。在治疗前、治疗后0.5小时、1小时、3小时、4小时、6小时、12小时以及1天、2天、3天、7天和30天采集血浆样本。选择4名患者在治疗后6小时、18小时、30小时和3天进行结节切除术和皮肤活检。利用这些样本,将盘尾丝虫虫体片段从宿主结节组织中分离出来以提取伊维菌素。伊维菌素在6小时时存在于结节组织中,并持续3天。在单个虫体组织提取物中也检测到了伊维菌素,其浓度与结节中的相似,但在皮下筋膜组织中有时会发现更高的浓度。通过放射免疫测定法在所有患者血浆中1小时时检测到伊维菌素,平均在5.6小时时达到峰值浓度。在70%的研究患者中,该药物在可检测水平持续了7天。还在16名接受治疗的墨西哥盘尾丝虫病患者伊维菌素治疗前、治疗4小时后以及6名作为对照的个体中采集了血浆样本。墨西哥患者血浆中伊维菌素的浓度与苏丹患者相似。

相似文献

1
Ivermectin uptake and distribution in the plasma and tissue of Sudanese and Mexican patients infected with Onchocerca volvulus.伊维菌素在感染盘尾丝虫的苏丹和墨西哥患者血浆及组织中的摄取与分布。
Trop Med Parasitol. 1991 Jun;42(2):79-81.
2
Ivermectin distribution in the plasma and tissues of patients infected with Onchocerca volvulus.伊维菌素在感染盘尾丝虫的患者血浆和组织中的分布。
Eur J Clin Pharmacol. 1996;50(5):407-10. doi: 10.1007/s002280050131.
3
The entry of ivermectin and suramin into Onchocerca ochengi nodules.伊维菌素和苏拉明进入盘尾丝虫奥氏亚种结节的过程。
Ann Trop Med Parasitol. 1997 Jun;91(4):393-401. doi: 10.1080/00034989761012.
4
Chemokines in onchocerciasis patients after a single dose of ivermectin.单剂量伊维菌素治疗后盘尾丝虫病患者体内的趋化因子
Clin Exp Immunol. 2005 Nov;142(2):318-26. doi: 10.1111/j.1365-2249.2005.02910.x.
5
Ivermectin treatment in severe asymmetric reactive onchodermatitis (sowda) in Sudan.
Trans R Soc Trop Med Hyg. 1995 May-Jun;89(3):312-5. doi: 10.1016/0035-9203(95)90559-6.
6
Evaluation of suramin, ivermectin and CGP 20376 in a new macrofilaricidal drug screen, Onchocerca ochengi in African cattle.在一项新的杀成虫药物筛选中对苏拉明、伊维菌素和CGP 20376进行评估,非洲牛体内的奥氏盘尾丝虫。
Trop Med Parasitol. 1995 Mar;46(1):31-7.
7
The chemotherapy of onchocerciasis. XIX: The clinical and laboratory tolerance of high dose ivermectin.盘尾丝虫病的化疗。第十九部分:高剂量伊维菌素的临床和实验室耐受性
Trop Med Parasitol. 1995 Jun;46(2):131-7.
8
Ivermectin in the treatment of onchocerciasis in Britain.
Trop Med Parasitol. 1991 Jun;42(2):82-4.
9
Absence of sperm from the seminal receptacle of female Onchocerca volvulus following multiple doses of ivermectin.
Trop Med Parasitol. 1993 Sep;44(3):155-8.
10
Eosinophil sequestration and activation are associated with the onset and severity of systemic adverse reactions following the treatment of onchocerciasis with ivermectin.伊维菌素治疗盘尾丝虫病后,嗜酸性粒细胞的隔离和激活与全身不良反应的发生及严重程度相关。
J Infect Dis. 1999 Mar;179(3):738-42. doi: 10.1086/314647.

引用本文的文献

1
Ivermectin Inhibits Zika Virus Replication in Vitro But Does Not Prevent Zika Virus Infection in Rhesus Macaques (Macaca mulatta).伊维菌素在体外可抑制寨卡病毒复制,但不能预防恒河猴(猕猴)感染寨卡病毒。
Am J Trop Med Hyg. 2024 Dec 17;112(3):648-656. doi: 10.4269/ajtmh.24-0183. Print 2025 Mar 5.
2
Pharmacokinetics of ivermectin metabolites and their activity against Anopheles stephensi mosquitoes.伊维菌素代谢物的药代动力学及其对致倦库蚊的活性。
Malar J. 2023 Jun 24;22(1):194. doi: 10.1186/s12936-023-04624-0.
3
PBPK modeling of ivermectin-Considerations for the purpose of developing alternative routes to optimize its safety profile.
伊维菌素的 PBPK 建模——考虑开发替代途径以优化其安全性特征的目的。
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):598-609. doi: 10.1002/psp4.12950. Epub 2023 Mar 15.
4
Intravenous veterinary ivermectin in a COVID-19 patient causing neurotoxicity.静脉注射兽用伊维菌素致一名新冠肺炎患者发生神经毒性
IDCases. 2022;27:e01446. doi: 10.1016/j.idcr.2022.e01446. Epub 2022 Feb 7.
5
Ivermectin treatment in humans for reducing malaria transmission.伊维菌素治疗人类以减少疟疾传播。
Cochrane Database Syst Rev. 2021 Jun 29;6(6):CD013117. doi: 10.1002/14651858.CD013117.pub2.
6
Clinically Approved Antiviral Drug in an Orally Administrable Nanoparticle for COVID-19.用于治疗新冠肺炎的口服纳米颗粒中的临床批准抗病毒药物。
ACS Pharmacol Transl Sci. 2020 Dec 1;3(6):1371-1380. doi: 10.1021/acsptsci.0c00179. eCollection 2020 Dec 11.
7
Orally Administrable Therapeutic Synthetic Nanoparticle for Zika Virus.口服给药治疗寨卡病毒的合成纳米颗粒。
ACS Nano. 2019 Oct 22;13(10):11034-11048. doi: 10.1021/acsnano.9b02807. Epub 2019 Oct 11.
8
Pharmacokinetics of ascending doses of ivermectin in Trichuris trichiura-infected children aged 2-12 years.阿维菌素在 2-12 岁感染鞭虫的儿童中递增剂量的药代动力学。
J Antimicrob Chemother. 2019 Jun 1;74(6):1642-1647. doi: 10.1093/jac/dkz083.
9
Ivermectin to reduce malaria transmission I. Pharmacokinetic and pharmacodynamic considerations regarding efficacy and safety.伊维菌素用于减少疟疾传播。I. 关于疗效和安全性的药代动力学和药效学考量。
Malar J. 2017 Apr 24;16(1):161. doi: 10.1186/s12936-017-1801-4.
10
Ivermectin: a complimentary weapon against the spread of malaria?伊维菌素:对抗疟疾传播的辅助武器?
Expert Rev Anti Infect Ther. 2017 Mar;15(3):231-240. doi: 10.1080/14787210.2017.1271713. Epub 2016 Dec 29.